ReviewMicrobial biotechnology2025
Phage-Antibiotic Combinations for Pseudomonas: Successes in the Clinic and In Vitro Tenuously Connected.
Review in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Systematic combinatorial optimization of three-phage cocktails against multidrug-resistantMicrobiology spectrum · 2026Article
- Artificial Intelligence in Bacteriophage Science: A Comprehensive Narrative Review of Applications, Challenges, and Translational Opportunities.Antibiotics (Basel, Switzerland) · 2026Review
- Comparison and correlation of in vitro and in vivo approaches for determining Pseudomonas aeruginosa bacteriophages activity.BMC microbiology · 2026Article
- Engineering a T7 bacteriophage to attenuate LPS-driven inflammatory responses during bacteriolysis.Applied and environmental microbiology · 2026Article
- Reimagining Phage Therapy for MDR Pathogens: From Biobanks to Health System Integration-A Review.Infectious diseases and therapy · 2026Review
- Phage-quinolone synergy: mechanisms, clinical strategies, and translational prospects.Frontiers in microbiology · 2026Review
- Immuno-phage synergy driven by fitness costs: turning bacterial phage resistance into therapeutic gain through evolutionary traps.Frontiers in immunology · 2026Review
- Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases.Frontiers in cellular and infection microbiology · 2026Review
- Phage Encapsulation and Delivery Technology: A Strategy for Treating Drug-Resistant Pathogenic Microorganisms.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Bacteriophage-Based Approach Against Biofilm Infections Associated with Medical Devices: A Narrative Review of ESKAPE Pathogens.International journal of molecular sciences · 2025Review
- Phage-Antibiotic Combinations for Pseudomonas: Successes in the Clinic and In Vitro Tenuously Connected.Microbial biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Antimicrobial resistance challenges researchers to innovate strategies to enhance the effectiveness of our existing antibiotics. Bacteriophage (phage, bacterial virus)-antibiotic combinations present a promising synergistic approach, particularly for drug-resistant infections such as those caused by Pseudomonas aeruginosa. This approach offers many advantages: enhanced bacterial killing (both planktonic and biofilm), eliminating persister cells, re-sensitization to drugs, and inhibiting resistance spread by targeting plasmids encoding resistant genes. Interestingly, even phages traditionally excluded from therapy - those capable of entering dormancy in the bacterial host - exhibit unique, potent synergy with antibiotics. Despite these clear in vitro benefits and the comparatively strong performance of phage antibiotic combinations in the clinic, translating in vitro efficacy to patient outcomes remain challenging. The lack of standardized metrics for measuring phage-antibiotic interaction complicates cross-study comparisons. In many instances, it is also difficult to translate these in vitro findings to clinically relevant metrics - for example, increased progeny size in vitro is unlikely to contribute meaningfully to treatment success. Addressing these gaps will allow us to fully harness the potential of phage-antibiotic combinations and bridge the disconnect between in vitro results and clinical success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.